GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition

Aidan G. Gilmartin(GlaxoSmithKline (United States)), Sylvie Laquerre(GlaxoSmithKline (United States))

Clinical Cancer Research

January 19, 2011

10.1158/1078-0432.ccr-10-2200

Cited by 600

Related Papers

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

|PLoS ONE|2013|216

JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-G

|iScience|2025|5